New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 11, 2012
18:16 EDTTHRXTheravance initiates Phase 2b study with TD-4208
Theravance announced the initiation of a dose ranging Phase 2b study with TD-4208 as a nebulized aqueous solution in patients with moderate to severe COPD. TD-4208 is an investigational inhaled long-acting muscarinic antagonist, discovered using Theravance's multivalent approach to drug design. This compound is under development by Theravance for the treatment of chronic obstructive pulmonary disease, or COPD.
News For THRX From The Last 14 Days
Check below for free stories on THRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for THRX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use